Cargando…
Phase 1 results of a phase 1b/2, multicenter, open-label trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) vs ipi alone in previously untreated, unresected stage IIIB-IV melanoma
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991001/ http://dx.doi.org/10.1186/2051-1426-1-S1-P84 |
| _version_ | 1782312363143200768 |
|---|---|
| author | Puzanov, Igor Milhem, Mohammed Andtbacka, Robert Minor, David Hamid, Omid Li, Ai VanderWalde, Ari Kaufman, Howard |
| author_facet | Puzanov, Igor Milhem, Mohammed Andtbacka, Robert Minor, David Hamid, Omid Li, Ai VanderWalde, Ari Kaufman, Howard |
| author_sort | Puzanov, Igor |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-3991001 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2013 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-39910012014-05-01 Phase 1 results of a phase 1b/2, multicenter, open-label trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) vs ipi alone in previously untreated, unresected stage IIIB-IV melanoma Puzanov, Igor Milhem, Mohammed Andtbacka, Robert Minor, David Hamid, Omid Li, Ai VanderWalde, Ari Kaufman, Howard J Immunother Cancer Poster Presentation BioMed Central 2013-11-07 /pmc/articles/PMC3991001/ http://dx.doi.org/10.1186/2051-1426-1-S1-P84 Text en Copyright © 2013 Puzanov et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Poster Presentation Puzanov, Igor Milhem, Mohammed Andtbacka, Robert Minor, David Hamid, Omid Li, Ai VanderWalde, Ari Kaufman, Howard Phase 1 results of a phase 1b/2, multicenter, open-label trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) vs ipi alone in previously untreated, unresected stage IIIB-IV melanoma |
| title | Phase 1 results of a phase 1b/2, multicenter, open-label trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) vs ipi alone in previously untreated, unresected stage IIIB-IV melanoma |
| title_full | Phase 1 results of a phase 1b/2, multicenter, open-label trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) vs ipi alone in previously untreated, unresected stage IIIB-IV melanoma |
| title_fullStr | Phase 1 results of a phase 1b/2, multicenter, open-label trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) vs ipi alone in previously untreated, unresected stage IIIB-IV melanoma |
| title_full_unstemmed | Phase 1 results of a phase 1b/2, multicenter, open-label trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) vs ipi alone in previously untreated, unresected stage IIIB-IV melanoma |
| title_short | Phase 1 results of a phase 1b/2, multicenter, open-label trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) vs ipi alone in previously untreated, unresected stage IIIB-IV melanoma |
| title_sort | phase 1 results of a phase 1b/2, multicenter, open-label trial to evaluate safety and efficacy of talimogene laherparepvec (t-vec) and ipilimumab (ipi) vs ipi alone in previously untreated, unresected stage iiib-iv melanoma |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991001/ http://dx.doi.org/10.1186/2051-1426-1-S1-P84 |
| work_keys_str_mv | AT puzanovigor phase1resultsofaphase1b2multicenteropenlabeltrialtoevaluatesafetyandefficacyoftalimogenelaherparepvectvecandipilimumabipivsipialoneinpreviouslyuntreatedunresectedstageiiibivmelanoma AT milhemmohammed phase1resultsofaphase1b2multicenteropenlabeltrialtoevaluatesafetyandefficacyoftalimogenelaherparepvectvecandipilimumabipivsipialoneinpreviouslyuntreatedunresectedstageiiibivmelanoma AT andtbackarobert phase1resultsofaphase1b2multicenteropenlabeltrialtoevaluatesafetyandefficacyoftalimogenelaherparepvectvecandipilimumabipivsipialoneinpreviouslyuntreatedunresectedstageiiibivmelanoma AT minordavid phase1resultsofaphase1b2multicenteropenlabeltrialtoevaluatesafetyandefficacyoftalimogenelaherparepvectvecandipilimumabipivsipialoneinpreviouslyuntreatedunresectedstageiiibivmelanoma AT hamidomid phase1resultsofaphase1b2multicenteropenlabeltrialtoevaluatesafetyandefficacyoftalimogenelaherparepvectvecandipilimumabipivsipialoneinpreviouslyuntreatedunresectedstageiiibivmelanoma AT liai phase1resultsofaphase1b2multicenteropenlabeltrialtoevaluatesafetyandefficacyoftalimogenelaherparepvectvecandipilimumabipivsipialoneinpreviouslyuntreatedunresectedstageiiibivmelanoma AT vanderwaldeari phase1resultsofaphase1b2multicenteropenlabeltrialtoevaluatesafetyandefficacyoftalimogenelaherparepvectvecandipilimumabipivsipialoneinpreviouslyuntreatedunresectedstageiiibivmelanoma AT kaufmanhoward phase1resultsofaphase1b2multicenteropenlabeltrialtoevaluatesafetyandefficacyoftalimogenelaherparepvectvecandipilimumabipivsipialoneinpreviouslyuntreatedunresectedstageiiibivmelanoma |